Qiagen has signed a master collaboration agreement with global pharmaceutical company Astellas Pharma to develop and commercialise companion diagnostics, combined with the latter’s drugs for use in cancer and other diseases.

As part of the agreement, Astellas will access Qiagen’s development capabilities for assays based on polymerase chain reaction (PCR) next generation sequencing (NGS) and multi-modal testing technologies using liquid and tissue biopsies.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Qiagen chief executive officer Peer Schatz said: "We are very pleased to partner with Astellas to help maximise the benefits of their innovative new drugs with companion diagnostics from our development and commercialisation engine.

"Qiagen shares Astellas commitment to contribute actively toward improving the health of patients by realising the benefits of personalised healthcare.

"The two projects, which will focus on oncology, intend to pair Qiagen diagnostics with Astellas compounds in early stage clinical trials."

The team will initial work on two projects including ASP5878, a fibroblast growth factor receptor (FGFR) inhibitor, and ASP8273, an epidermal growth factor receptor (EGFR) inhibitor.

See Also:

The two projects, which will focus on oncology, intend to pair Qiagen diagnostics with Astellas compounds in early stage clinical trials.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Schatz said: "With the master agreement and the first two projects to be disclosed, Qiagen is further expanding its leadership in personalised medicine, including in Japan, one of the world’s largest markets for companion diagnostics.

"The master agreement provides Astellas and Qiagen flexibility and a strong foundation to add further development projects across other therapeutic areas, across analytical techniques, and across a broad array of sampling options."